TransMedics set a target of 10,000 U.S. National OCS Program (NOP) cases by 2028. The company aims to reach 20,000 annual cases by 2030. Management expects to achieve the 10,000-case goal based on existing assumptions. The 20,000-case target relies on future catalysts.
The company anticipates FDA approval for its OCS kidney platform by 2029. TransMedics plans to deploy OCS 3.0 technology for liver, heart, and lung transplants between 2029 and 2030.
Europe represents 50% of the global transplant market and serves as the primary international expansion target. The company will establish its NOP-centric model in Italy to address regional logistical and staffing challenges.